This department is offering a grant to support the creation of Laboratories aimed at conducting early clinical evaluation of potential pharmacotherapies for Substance Use Disorders (SUDs). The goal is to accelerate the clinical development of medications to treat SUDs by facilitating FDA-defined Phase 1 and/or Phase 2 clinical trials of new or repurposed compounds. Clinical investigators are encouraged to apply for this grant to establish Laboratories with the necessary expertise and resources to efficiently conduct trials for the treatment of SUDs. Closing date for applications is March 15, 2019.
Opportunity ID: 311487
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | RFA-DA-19-018 |
| Funding Opportunity Title: | Laboratories for Early Clinical Evaluation of Pharmacotherapies for Substance Use Disorders (UG1 Clinical Trial Required) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement |
| Category of Funding Activity: | Education Health |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 93.279 — Drug Abuse and Addiction Research Programs |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Dec 21, 2018 |
| Last Updated Date: | Dec 21, 2018 |
| Original Closing Date for Applications: | Mar 15, 2019 |
| Current Closing Date for Applications: | Mar 15, 2019 |
| Archive Date: | Apr 20, 2019 |
| Estimated Total Program Funding: | – |
| Award Ceiling: | $500,000 |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Special district governments Small businesses Public housing authorities/Indian housing authorities Native American tribal organizations (other than Federally recognized tribal governments) Native American tribal governments (Federally recognized) Others (see text field entitled “Additional Information on Eligibility” for clarification) City or township governments County governments For profit organizations other than small businesses Private institutions of higher education State governments Independent school districts Public and State controlled institutions of higher education Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are not allowed. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: | This Funding Opportunity Announcement (FOA) invites applications from clinical investigators to take part in the creation of Laboratories for Early Clinical Evaluation of Pharmacotherapies for Substance Use Disorders (SUDs). The purpose of this Funding Opportunity Announcement (FOA) is to support the creation of Laboratories with expertise and resources to conduct early clinical evaluation of potential pharmacotherapies for Substance Use Disorders (SUDs). The goal is to accelerate the clinical development of medications to treat Substance Use Disorders (SUDs) by supporting Laboratories with expertise and resources to timely and efficiently conducting FDA-defined Phase 1 and/or Phase 2 clinical trials of new or repurposed compounds to treat SUDs. the clinical development of medications to treat Substance Use Disorders (SUD) by supporting laboratories with the expertise and resources to timely and efficiently conduct early (Phase 1 or Phase 2) clinical trials of potential pharmacotherapies for SUDs. |
| Link to Additional Information: | http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-19-018.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV Email:FBOWebmaster@OD.NIH.GOV |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
Related Documents
There are no related documents on this grant.
Packages
| Agency Contact Information: | NIH OER Webmaster FBOWebmaster@OD.NIH.GOV Email: FBOWebmaster@OD.NIH.GOV |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| FORMS-E | FORMS-E | PKG00247137 | Feb 15, 2019 | Mar 15, 2019 | View |
Package 1
Mandatory forms
311487 RR_SF424_2_0-2.0.pdf
311487 PHS398_CoverPageSupplement_4_0-4.0.pdf
311487 RR_OtherProjectInfo_1_4-1.4.pdf
311487 PerformanceSite_2_0-2.0.pdf
311487 RR_KeyPersonExpanded_2_0-2.0.pdf
311487 RR_Budget_1_4-1.4.pdf
311487 PHS398_ResearchPlan_4_0-4.0.pdf
Optional forms
311487 RR_SubawardBudget30_1_4-1.4.pdf
311487 PHS_AssignmentRequestForm_2_0-2.0.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
